CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Chicago, Illinois, United States and 51 other locations
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Chicago, Illinois, United States and 173 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Chicago, Illinois, United States and 56 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Maywood, Illinois, United States and 23 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Chicago, Illinois, United States and 22 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Chicago, Illinois, United States and 13 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in a...
Phase 1
Chicago, Illinois, United States and 23 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Chicago, Illinois, United States and 43 other locations
(a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia...
Phase 1
Chicago, Illinois, United States and 3 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Chicago, Illinois, United States and 110 other locations
Clinical trials
Research sites
Resources
Legal